SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal
Executive Summary
Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Stellar Survival Data For AZ's Lynparza Hailed At ESMO
Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.